Market Access Strategy for Medical Devices in Europe
Strategic recommendations on the topic of market access pathways for medical devices and IVD tests
White Paper: Evidence requirements for coverage of medical technologies in the Netherlands
Get insights from MTRC White Papers to advance your understanding of five rapid HTA reports from the Netherlands
Recent news and posts
Coverage positions published by the Dutch Healthcare Institute in Q1-Q2 2025
In the first and second quarters of 2025, the Dutch Healthcare Institute (ZIN) published three coverage positions.
Two favorable recommendations were made for the inclusion in the basic health insurance of the following procedures/technologies:
- Internal nasal valve correction in airway blockage: This procedure was deemed to have added clinical value, and its reimbursement under the basic health insurance became effective on May 15, 2025, for patients with long-term, severe nasal airway obstruction.
- Molecular diagnostics of the NTRK gene fusion in cancer patients: ZIN recommended reimbursement of Whole Genome Sequencing (WGS) as an alternative to Next-Generation Sequencing (NGS) for detecting NTRK gene fusion (to support treatment decisions about NTRK inhibitors). Since NGS has already been reimbursed, the decision extends coverage to WGS, with retroactive effect from June 24, 2025.
Moreover, one procedure in the gastrointestinal field was not recommended for coverage under the basic health insurance.
The full details in Dutch can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.